Shenzhen S.E.
06:00:00 2024-04-22 pm EDT
5-day change
1st Jan Change
21.27
CNY
-3.36%
+5.56%
-3.23%
Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022
May 25, 2022 at 03:33 pm EDT
Amoy Diagnostics Co., Ltd. approved 2021 profit distribution plan with cash dividend (tax included) of CNY 2.30000000 per 10 shares. Record date: 30 May 2022, Ex-date: 31May 2022 and Payment date: 31 May 2022.
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 22
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 15
CI
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.
Apr. 01
CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index
Dec. 11
CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index
Dec. 11
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-23
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-07-31
CI
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China
23-07-26
MT
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023
23-05-16
CI
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022
23-05-12
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-21
CI
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022
23-04-17
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-14
CI
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC
23-03-27
CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
23-02-14
CI
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million.
23-02-12
CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
23-01-03
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-24
CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
22-10-10
CI
Alercell® to Distribute Amoydx® Ros1 Gene Fusion Detection Kit
22-08-08
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-07-29
CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
22-07-04
CI
Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022
22-05-25
CI
Amoy Diagnostics Co., Ltd. Approves Dividend for 2021
22-05-12
CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Companyâs testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
More about the company
Last Close Price
21.27
CNY
Average target price
29.55
CNY
Spread / Average Target
+38.92%
Consensus
1st Jan change
Capi.
-3.23% 1.16B +0.80% 12.82B -12.75% 7.4B +2.81% 5.47B -1.37% 4.51B +3.89% 4.42B -50.71% 3.29B +9.29% 2.66B -15.10% 2.07B -2.82% 1.68B
Diagnostic & Testing Substances
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
AMOY DIAGNOSTICS CO., LTD. 
